Damora Therapeutics Inc（DMRA）資訊與事件

$29.000

-1.517 (-5.23%)收盤時

DMRA 資訊

8.507-17Newsfilter

Damora Therapeutics Completes Redomestication to Cayman Islands

8.505-30NASDAQ.COM

FCPM III Services B.V. Initiates Position in Damora Therapeutics

8.505-30Fool

FCPM III Acquires Significant Stake in Damora Therapeutics

9.505-12seekingalpha

Galecto Reports Q1 Earnings Miss with CEO Appointment

5.003-23seekingalpha

Damora Therapeutics Appoints New CEO and Board Members

5.003-23moomoo

Damora Therapeutics Names Biotechnology Expert Jennifer Jarrett as President and CEO; Welcomes Two Industry Veterans to Board of Directors

9.503-20NASDAQ.COM

Damora Therapeutics Reports 2025 Results and Pipeline Progress

9.503-19seekingalpha

Galecto Reports Disappointing FY Earnings with Significant EPS Miss

查看更多資訊

DMRA 事件

3/23 08:20

Damora Therapeutics Appoints Jennifer Jarrett as CEO

Damora Therapeutics (DMRA) announced that its board of directors has appointed Jennifer Jarrett as president and CEO, effective March 30. Jarrett will also serve on the company's board of directors. Most recently, she served as COO of Arcus Biosciences (RCUS).

3/23 08:20

Damora Therapeutics Appoints New Board Members

Damora Therapeutics (DMRA) also announced the appointment of Cameron Turtle, CEO of Spyre Therapeutics (SYRE) to the company's board of directors. In addition, Peter Harwin, founding partner at Fairmount Funds Management, and a current member of Damora's board of directors, has been named chairman.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。